Boston Scientific Europe today announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart...

Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...

Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...

Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...

Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...

MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...

Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...

SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...

Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...

Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...

Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...

Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...

Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...

Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week in the European Heart Journal. The interim...

In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX) exclusively sponsored and landmark...

Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads. Pacing leads...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac...

Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The completion of this...

An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity...

In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...

The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...

Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter...